Dec 31, 2025 • MarketBeat
SOMEWHAT-BULLISH
Shum Financial Group Inc. Acquires Shares of 8,127 Abbott Laboratories $ABT
Shum Financial Group Inc. has acquired a new position of 8,127 shares in Abbott Laboratories (NYSE:ABT) during the third quarter, valued at approximately $1,088,000. Abbott Laboratories recently increased its quarterly dividend to $0.63, resulting in an annualized dividend of $2.52 and a yield of 2.0%. The company reported Q3 EPS of $1.30, meeting analyst estimates, and provided FY2025 guidance of $5.12–$5.18 EPS, with analysts assigning an average "Moderate Buy" rating and a $147 target price.
Dec 31, 2025 • MarketBeat
BULLISH
VIRGINIA RETIREMENT SYSTEMS ET Al Purchases 245,400 Shares of Abbott Laboratories $ABT
VIRGINIA RETIREMENT SYSTEMS ET Al significantly increased its stake in Abbott Laboratories (NYSE:ABT) by acquiring an additional 245,400 shares, bringing its total holdings to 826,268 shares valued at $110.67 million. This makes Abbott Laboratories the 22nd biggest position for the institutional investor, comprising 0.7% of its total holdings. The article also details other institutional investor activities, analyst ratings, and the company's recent financial performance and dividend increase.
Dec 31, 2025 • MarketBeat
SOMEWHAT-BULLISH
Brendel Financial Advisors LLC Sells 23,978 Shares of Abbott Laboratories $ABT
Brendel Financial Advisors LLC decreased its holdings in Abbott Laboratories by 75.4% in Q3, selling 23,978 shares and leaving it with 7,816 shares valued at $1.05 million. Meanwhile, major institutions like Vanguard and Norges Bank significantly increased their stakes in ABT. Abbott reported Q3 EPS of $1.30, with revenue slightly below forecasts, issued FY2025 guidance of $5.12-$5.18 EPS, and raised its quarterly dividend to $0.63.
Dec 31, 2025 • openPR.com
SOMEWHAT-BULLISH
Epilepsy Drugs Market Is Booming Worldwide 2025-2032 | Pfizer Inc., Sumitomo Pharma Co., Ltd., Novartis AG
The global Epilepsy Drugs Market is projected to grow from USD 10.88 billion in 2025 to USD 15.83 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.5%. This growth is driven by rapid innovation, increasing investment, and shifting regional dynamics, necessitating strategic insights for decision-makers. The report provides a deep dive into market structure, segmenting it by type, application, and region, along with detailed profiles of key players to help navigate market opportunities.
Dec 31, 2025 • MarketBeat
SOMEWHAT-BULLISH
Ascent Group LLC Has $7.47 Million Holdings in AbbVie Inc. $ABBV
Ascent Group LLC increased its stake in AbbVie Inc. (NYSE:ABBV) by 49.2% in the third quarter, bringing their holdings to $7.47 million. Other institutional investors like Vanguard Group Inc. and Geode Capital Management LLC also increased their positions. Analysts have a "Moderate Buy" consensus rating for AbbVie with an average target price of $245.84, and the company recently announced an increased quarterly dividend of $1.73 per share.
Dec 31, 2025 • ts2.tech
BULLISH
Abbott stock today: ABT rises as Exact Sciences deal filing and Volt AFib device stay in focus
Abbott shares rose marginally as investors focused on two key catalysts: an SEC filing from acquisition target Exact Sciences detailing accelerated bonus payouts tied to "golden parachute" tax rules for its proposed deal with Abbott, and the ongoing U.S. rollout of Abbott's Volt pulsed field ablation system for atrial fibrillation. These developments are influencing the company's valuation as the year-end approaches, with market participants closely monitoring the deal's progress, Volt's commercial uptake, and Abbott's upcoming earnings report.